Achyut Healthcar (543499)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• The latest quarter shows positive sales of ₹2 Cr and a breakeven net profit of ₹0 Cr, not a loss.
• ROCE of 2.26% and ROE of 0.01% are positive, indicating some capital is being deployed rather than fully idle.
• Book value of ₹1.32 per share provides a tangible but small asset base.
• Sales growth is 0%, meaning operations are stable at ₹2 Cr quarterly rather than declining.

Concerns

• Valuation is dangerously high: P/E of 289.23, P/B of 36.36, and market cap of ₹1,187 Cr against quarterly sales of just ₹2 Cr.
• Profit growth is -100% and net profit is zero, so the company is currently earning almost nothing for shareholders.
• Piotroski F-Score of 3/9 points to weak financial health and potential red flags.
• No dividend yield, unknown promoter holding, and a 52-week range of ₹4.70 to ₹48.00 suggest speculative price action rather than fundamental value.

AI Analysis

Let's start by saying this is not the kind of investment I would make. At ₹48, the market capitalisation is ₹1,187 crore, yet the latest quarterly sales were just ₹2 crore. That means the stock trades at an absurd multiple of revenue. The P/E is meaningless at 289, because earnings are effectively zero. Profit growth has collapsed by 100%, and return on equity is 0.01%. When I buy a business, I look for a durable product, a moat, and a management that earns a good return on capital. Here, ROCE is only 2.26%, so even the operational return is pitiful. Book value is ₹1.32 per share, so you're paying 36 times book for a business with no growth in sales and no dividend. The Piotroski score of 3 out of 9 tells me financial health is poor. The 52-week range of ₹4.70 to ₹48 shows speculation, not fundamental value. A stock can go up only so long on hope; eventually earnings must justify the price. In Graham's words, price is what you pay, value is what you get. Here you are paying a fortune for very little value. The only 'strength' is that the company is not shrinking sales at the moment and isn't losing money – but that hardly matters when the price implies a near-perfect future. I would be a seller, not a buyer. If the business ever manages to grow sales from this tiny base, the stock may still be too expensive. Wait for either a much lower price or proven profitability and growth.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer